

Uppsala 2019-04-04

Pileseptin is now available for sale at Apotek Hjärtat

Double Bond Pharmaceuticals subsidiary Drugsson AB, distributor of Pileseptin in the Nordic market, reports that Pileseptin in both gel and spray form is now available at Apotek Hjärtat. Earlier this year the product became available at APOHEM, Apotea, Apotek365 and Meds.se in Sweden as well as on Webpharma in Norway.

"We are happy to now have our first marketed non-prescription product in one of the largest pharmacy chains in Sweden and we continue to work towards establishing deals with other sales channels in the future," comments Igor Lokot, CEO at Double Bond Pharmaceutical and Drugsson AB, - We are at the same time still interested in new, sought-after products that may be a good fit to Drugssons pipe line."

More about Pileseptin: It's a new treatment for hemorrhoids that works effectively by reducing swelling and keeping the area clean from bacteria and dirt. Pileseptin Spray is used against external hemorrhoids and Pileseptin Gel against internal hemorrhoids. Pileseptin is the only product of its kind to abate hemorrhoids and not just the symptoms.

More about Apotek Hjärtat: www.apotekhjartat.se

More about Drugsson AB: www.drugsson.com

Full Company Name: Double Bond Pharmaceutical International AB (publ)

Corporate identity: 556991-6082

Stock short name: DBP B

Share ISIN code: SE0007185525

For more info, contact

Igor Lokot, CEO



Homepage: <http://www.doublebp.com/>

E-mail: info@doublebp.com

Blog: <http://blog.doublebp.com>

Follow us on LinkedIn (<https://www.linkedin.com/company/double-bond-pharmaceutical?trk=co-feed-likes-one>) and Twitter (<https://twitter.com/DoubleBondPharm>)!

Information on Double Bond Pharmaceutical International AB

DBP is a pharmaceutical company with the primary focus on development of therapies against cancer based on the company's own developed drug delivery technology BeloGal®. The company was granted Orphan Drug Designation status by European Medicines Agency (EMA) in June 2015 for its first product, SA-033, for treatment of hepatoblastoma. Double Bond Pharmaceutical acquired rights to Temodex, a drug registered in Belarus for treatment of brain tumours, in October 2015, and was granted Orphan Drug Designation status by EMA for in July 2016 for this formulation of temozolomide for the treatment of glioma. The formulation is now being further developed for registration in EU and globally and has a working name SI-053 in DBP pipeline.